- Cue Biopharma (CUE, Financial) has scheduled a business update conference call and webcast for April 15, 2025, at 4:30 p.m. ET.
- The company focuses on developing biologics for cancer and autoimmune diseases through selective T cell modulation.
- The webcast will be accessible to investors and archived for 30 days following the presentation.
Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company based in Boston, Massachusetts, will host a business update conference call and webcast on Tuesday, April 15, 2025, at 4:30 p.m. ET. The company is renowned for its innovative approach to engaging and modulating disease-specific T cells for treating cancer and autoimmune diseases.
Investors in the United States can join the call by dialing 1-844-826-3035, while international participants can access the call using 1-412-317-5195, with the conference ID 10199037. A live webcast of the call will be available via the company's Investors and Media section on its website and will remain archived for 30 days post-presentation.
Cue Biopharma’s platform, Immuno-STAT™, is designed to harness the body's immune system's curative potential by selectively modulating T cells without broad systemic effects. The company invites investors and interested parties to tune in to the webcast for detailed insights into its therapeutic developments and strategic plans.
